ITP
MCID: THR001
MIFTS: 61

Thrombocytopenia Due to Platelet Alloimmunization (ITP)

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Thrombocytopenia Due to Platelet Alloimmunization

MalaCards integrated aliases for Thrombocytopenia Due to Platelet Alloimmunization:

Name: Thrombocytopenia Due to Platelet Alloimmunization 11 14 71
Immune Thrombocytopenia 11 19 42 58 75 14 63
Autoimmune Thrombocytopenia 42 58 28 53 5 71
Immune Thrombocytopenic Purpura 42 58 71
Itp 42 58
Thrombocytopenia Due to Immune Destruction 11
Idiopathic Thrombocytopenic Purpura 42
Autoimmune Thrombocytopenic Purpura 42
Auto-Immune Thrombocytopenia 11
Werlhof Disease 42

Characteristics:


Prevelance:

Immune Thrombocytopenia: 1-5/10000 (Europe, Denmark) 1-9/100000 (United States, United Kingdom, Denmark, France) 58

Age Of Onset:

Immune Thrombocytopenia: All ages 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:1587
NCIt 49 C3991
SNOMED-CT 68 2897005
MESH via Orphanet 44 D016553
ICD10 via Orphanet 32 D69.3
UMLS via Orphanet 72 C0242584 C0398650
UMLS 71 C0242584 C0272286 C0398650

Summaries for Thrombocytopenia Due to Platelet Alloimmunization

MedlinePlus Genetics: 42 Immune thrombocytopenia is a disorder characterized by a blood abnormality called thrombocytopenia, which is a shortage of blood cells called platelets that are needed for normal blood clotting.Affected individuals can develop red or purple spots on the skin caused by bleeding just under the skin's surface. Small spots of bleeding under the skin are called purpura and larger spots are called ecchymoses. People with immune thrombocytopenia can have significant bleeding episodes, such as nose bleeds (epistaxis) or bleeding in the moist lining (mucosae) of the mouth. In severe cases, individuals may have gastrointestinal bleeding or blood in the urine or stool, or heavy and prolonged menstrual bleeding (menorrhagia). In very rare instances, bleeding inside the skull (intracranial hemorrhage) can occur, which can be life-threatening. A greater reduction in platelet numbers is often associated with more frequent bleeding episodes and an increased risk of severe bleeding.While immune thrombocytopenia can be diagnosed at any age, there are two periods when the condition is most likely to develop: early childhood and late adulthood. In children, the reduction in platelets is often sudden, but platelet levels usually return to normal levels within weeks to months. Immune thrombocytopenia in children is often preceded by a minor infection, such as an upper respiratory infection, but the relationship between the infection and immune thrombocytopenia is not clear. In adults, the development of immune thrombocytopenia is usually gradual and the condition tends to persist throughout life.

MalaCards based summary: Thrombocytopenia Due to Platelet Alloimmunization, also known as immune thrombocytopenia, is related to purpura and splenic marginal zone lymphoma. An important gene associated with Thrombocytopenia Due to Platelet Alloimmunization is FCGR2C (Fc Gamma Receptor IIc (Gene/Pseudogene)), and among its related pathways/superpathways are Akt Signaling and Response to elevated platelet cytosolic Ca2+. The drugs Prednisolone phosphate and Prednisolone acetate have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and skin, and related phenotypes are thrombocytopenia and thromboembolism

PubMed Health : 63 Immune thrombocytopenia: Immune thrombocytopenia (THROM-bo-si-toe-PE-ne-ah), or ITP, is a bleeding disorder. In ITP, the blood doesn't clot as it should. This is due to a low number of blood cell fragments called platelets (PLATE-lets) or thrombocytes (THROM-bo-sites). Platelets are made in your bone marrow along with other kinds of blood cells. They stick together (clot) to seal small cuts or breaks on blood vessel walls and stop bleeding.

Orphanet: 58 A rare autoimmune coagulation disorder characterized by isolated thrombocytopenia (a platelet count <100,000/microL), in the absence of any underlying disorder that may be associated with thrombocytopenia.

Wikipedia: 75 Immune thrombocytopenic purpura (ITP), also known as idiopathic thrombocytopenic purpura or immune... more...

Related Diseases for Thrombocytopenia Due to Platelet Alloimmunization

Diseases in the Thrombocytopenia family:

Thrombocytopenia 2 Thrombocytopenia 3
Thrombocytopenia 1 Thrombocytopenia 4
Thrombocytopenia 5 Thrombocytopenia 6
Thrombocytopenia 7 Acquired Thrombocytopenia
Thrombocytopenia Due to Platelet Alloimmunization Primary Thrombocytopenia
Ankrd26-Related Thrombocytopenia

Diseases related to Thrombocytopenia Due to Platelet Alloimmunization via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1336)
# Related Disease Score Top Affiliating Genes
1 purpura 32.2 THPO SELP PF4 MPL ITGB3 ITGA2B
2 splenic marginal zone lymphoma 31.9 U2AF1 CD19 CCR6
3 evans' syndrome 31.8 U2AF1 THPO MPL CD8A CD4 CD19
4 thrombocytopenic purpura, autoimmune 31.4 THPO SOCS1 SELP PF4 MPL ITGB3
5 antiphospholipid syndrome 31.1 SELP PF4 GP1BA
6 acquired thrombocytopenia 31.1 THPO MPL ITGB3 ITGA2B GP1BA
7 thrombocytosis 31.0 U2AF1 THPO SELP PF4 MPL
8 colitis 30.9 SYK SOCS1 ICOSLG CD4 CCR6
9 human cytomegalovirus infection 30.9 CD8A CD4 CCR6
10 henoch-schoenlein purpura 30.9 ICOSLG CD4 CCR6
11 chickenpox 30.9 CD8A CD4 CD19 CCR6
12 crohn's disease 30.9 ICOSLG CD8A CD4 CCR6
13 dengue disease 30.9 CD8A CD4 CCR6
14 qualitative platelet defect 30.9 THPO SELP ITGA2B GP1BA
15 thrombocytopenia 30.9 U2AF1 THPO SYK SOCS1 SELP PF4
16 infective endocarditis 30.8 ITGA2B GP1BA CCR6
17 hemorrhagic disease 30.8 THPO PF4 ITGA2B GP1BA CD4
18 autoimmune polyendocrine syndrome 30.8 ICOSLG CD4 CCR6
19 immune deficiency disease 30.8 SYK ICOSLG FCGR2A CD8A CD4 CCR6
20 pernicious anemia 30.8 ICOSLG CD4 CCR6
21 exanthem 30.8 ICOSLG CD8A CD4 CD19 CCR6
22 severe cutaneous adverse reaction 30.8 CD8A CD4 CCR6
23 thrombosis 30.8 SELP PF4 MPL ITGB3 ITGA2B GP1BA
24 anemia, autoimmune hemolytic 30.8 SOCS1 ICOSLG CD8A CD4 CD19 CCR6
25 portal vein thrombosis 30.7 THPO PF4 MPL
26 thrombasthenia 30.7 SELP ITGB3 ITGA2B GP1BA
27 hemoglobinuria 30.7 THPO SELP MPL
28 heparin-induced thrombocytopenia 30.7 PF4 ITGB3 ITGA2B FCGR2A
29 von willebrand's disease 30.7 SELP ITGA2B GP1BA
30 myelofibrosis 30.7 U2AF1 THPO SELP MPL
31 celiac disease 1 30.6 ICOSLG CD8A CD4 CD19 CCR6
32 hypersplenism 30.6 U2AF1 THPO CD4
33 orchitis 30.6 CD8A CD4 CCR6
34 agammaglobulinemia, x-linked 30.6 SYK ICOSLG CD19 CCR6
35 glanzmann thrombasthenia 1 30.6 SELP PF4 ITGB3 ITGA2B GP1BA
36 poliomyelitis 30.6 FCGR2A CD8A CD4
37 proliferative glomerulonephritis 30.5 SELP ICOSLG CCR6
38 primary biliary cholangitis 30.5 ICOSLG CD8A CD4 CCR6
39 igg4-related disease 30.5 ICOSLG CD4 CD19 CCR6
40 fetal and neonatal alloimmune thrombocytopenia 30.5 ITGB3 ITGA2B GP1BA
41 sclerosing cholangitis 30.5 ICOSLG CD8A CD4 CCR6
42 myelitis 30.5 ITGB3 ITGA2B CCR6
43 hematologic cancer 30.5 U2AF1 THPO SYK MPL ICOSLG CCR6
44 diffuse large b-cell lymphoma 30.5 U2AF1 ICOSLG CD19 CCR6
45 herpes zoster 30.5 FCGR2A CD8A CD4 CCR6
46 cholangitis, primary sclerosing 30.5 ICOSLG CD8A CD4 CCR6
47 childhood type dermatomyositis 30.5 ICOSLG CD4 CCR6
48 autoimmune pancreatitis 30.5 ICOSLG CD4 CCR6
49 hypersensitivity vasculitis 30.5 ICOSLG CD4 CCR6
50 aplastic anemia 30.5 U2AF1 THPO MPL GP1BA CD8A CD4

Graphical network of the top 20 diseases related to Thrombocytopenia Due to Platelet Alloimmunization:



Diseases related to Thrombocytopenia Due to Platelet Alloimmunization

Symptoms & Phenotypes for Thrombocytopenia Due to Platelet Alloimmunization

Human phenotypes related to Thrombocytopenia Due to Platelet Alloimmunization:

58 30 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 thrombocytopenia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001873
2 thromboembolism 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001907
3 petechiae 58 30 Frequent (33%) Frequent (79-30%)
HP:0000967
4 arterial thrombosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0004420
5 gastrointestinal hemorrhage 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002239
6 epistaxis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000421
7 gingival bleeding 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000225
8 bruising susceptibility 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000978
9 cerebral hemorrhage 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001342
10 purpura 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Thrombocytopenia Due to Platelet Alloimmunization:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.21 CCR6 CD19 CD4 FCGR2A FCGR2C FCGRT
2 cellular MP:0005384 9.93 CD19 CD4 CD8A FCGR2A FCGR2C GP1BA
3 renal/urinary system MP:0005367 9.92 CD19 CD8A FCGR2A FCGR2C ITGB3 SELP
4 immune system MP:0005387 9.86 CCR6 CD19 CD4 CD8A FCGR2A FCGR2C
5 hematopoietic system MP:0005397 9.58 CCR6 CD19 CD4 CD8A FCGR2A FCGR2C

Drugs & Therapeutics for Thrombocytopenia Due to Platelet Alloimmunization

PubMed Health treatment related to Thrombocytopenia Due to Platelet Alloimmunization: 63

Treatment for immune thrombocytopenia (ITP) is based on how much and how often you're bleeding and your platelet count. Adults who have mild ITP may not need any treatment , other than watching their symptoms and platelet counts. Adults who have ITP with very low platelet counts or bleeding problems often are treated. The acute (short-term) type of ITP that occurs in children often goes away within a few weeks or months. Children who have bleeding symptoms, other than merely bruising (purpura ), usually are treated. Children who have mild ITP may not need treatment other than monitoring and followup to make sure their platelet counts return to normal.

Drugs for Thrombocytopenia Due to Platelet Alloimmunization (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 183)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
2
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
4
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
6
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
7
Clarithromycin Approved Phase 4 81103-11-9 84029
8
Hydroxychloroquine Approved Phase 4 118-42-3 3652
9
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6 9578005
10
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
11
Alemtuzumab Approved, Investigational Phase 4 216503-57-0
12
Morphine Approved, Investigational Phase 4 57-27-2 5288826
13
Glycyrrhizic acid Approved, Experimental Phase 4 1405-86-3 3495 14982
14
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
15
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453
16
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
17
3,4-Dihydroxycinnamic Acid Experimental, Investigational Phase 4 331-39-5, 501-16-6 689043
18
Enoxolone Investigational Phase 4 471-53-4 3230 18526330 10114
19 Vitamins Phase 4
20 Calciferol Phase 4
21 Calcium, Dietary Phase 4
22 Trace Elements Phase 4
23 Vasoconstrictor Agents Phase 4
24 Micronutrients Phase 4
25 Tin Fluorides Phase 4
26 Anti-Infective Agents Phase 4
27 gamma-Globulins Phase 4
28 Rho(D) Immune Globulin Phase 4
29 Neuroprotective Agents Phase 4
30
Methylprednisolone Acetate Phase 4 584547
31 Protective Agents Phase 4
32 Antiprotozoal Agents Phase 4
33 Antiparasitic Agents Phase 4
34 Antimalarials Phase 4
35 Proton Pump Inhibitors Phase 4
36 Cytochrome P-450 Enzyme Inhibitors Phase 4
37 Cytochrome P-450 CYP3A Inhibitors Phase 4
38 Antimitotic Agents Phase 4
39 Tubulin Modulators Phase 4
40 Anti-Ulcer Agents Phase 4
41 Antacids Phase 4
42
Calcium Nutraceutical Phase 4 7440-70-2 271
43
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
44
Dapsone Approved, Investigational Phase 3 80-08-0 2955
45
Hydrocortisone succinate Approved Phase 3 2203-97-6 3643
46
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
47
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 3640 5754
48
Pantoprazole Approved Phase 3 102625-70-7, 138786-67-1 4679
49
Selenium Approved, Investigational, Vet_approved Phase 2, Phase 3 7783-07-5, 7782-49-2 533
50
Acetaminophen Approved Phase 3 103-90-2 1983

Interventional clinical trials:

(show top 50) (show all 351)
# Name Status NCT ID Phase Drugs
1 Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia in Pediatrics Unknown status NCT04102033 Phase 4 Eltrombopag
2 Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial Unknown status NCT03771378 Phase 4 rhTPO;eltrombopag
3 A Multicenter Randomized Open-label Clinical Trial of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP Unknown status NCT04094805 Phase 4 Rocaltrol;Dexamethasone
4 Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura Unknown status NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
5 A Multicenter, Randomized, Open-label Study To Compare The Efficacy And Safety Of Eltrombopag Combining Rituximab With Eltrombopag In Adult ITP Patients Unknown status NCT04518475 Phase 4 eltrombopag combining rituximab;eltrombopag
6 Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in Immune Thrombocytopenia: a Prospective Multicenter Open Study Unknown status NCT03119974 Phase 4 Tpo-RA discontinuation
7 A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP) Completed NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
8 Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim Completed NCT02760251 Phase 4 romiplostim
9 The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia Completed NCT03258866 Phase 4 Rituximab
10 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
11 Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP) Completed NCT04089267 Phase 4 TPO
12 An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis Completed NCT01390649 Phase 4
13 Collection of Blood Samples From Patients With Relapsing Forms of Multiple Sclerosis (RMS) Who Have Developed Immune Thrombocytopenic Purpura (ITP) After LEMTRADA® Treatment Completed NCT03784898 Phase 4
14 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
15 A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4 Eltrombopag olamine
16 A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
17 Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag. Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
18 Short-course High-dose Prednisone and Dexamethasone in Children With Immune A Multicenter, Randomized Controlled Study of Thrombocytopenia Recruiting NCT05522465 Phase 4 Prednisone;Dexamethasone
19 Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) Recruiting NCT03866798 Phase 4
20 Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim Recruiting NCT04638829 Phase 4 Avatrombopag Oral Tablet
21 A Multicenter, Randomized Controlled Study of Two Regimens of Intravenous Immune Globulin in the Treatment of Newly Diagnosed Immune Thrombocytopenia in Children Recruiting NCT05520892 Phase 4 intravenous immunoglobulin
22 A Single-center Prospective Randomized Study of Glycyrrhetinic Acid Combined With Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03998982 Phase 4 Glycyrrhetinic Acid;Dexamethasone
23 Efficacy and Safety of Eltrombopag Combined With Low-dose Rituximab in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Fail to First-line Treatment: a Prospective, Open-label, Nonrandomized, Multicenter Clinical Trial Recruiting NCT04915482 Phase 4 Combined use of eltrombopag with low-dose rituximab;The best available therapy
24 A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency) Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
25 Efficacy and Safety of Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Fail to Eltrombopag or Herombopag Treatment: a Single-center, Prospective, One-arm Clinical Trial Recruiting NCT04993885 Phase 4 Avatrombopag
26 Comparing the Efficacy and Safety of Optimized rhTPO Treatment Versus Eltrombopag Treatment in Previously Treated Primary Immune Thrombocytopenia Patients: A Multicenter Randomized Open-label Trial Not yet recruiting NCT05583838 Phase 4 rhTPO;Eltrombopag
27 Efficacy and Safety of TPO Receptor Agonists as First-line Drugs in the Treatment of Newly Diagnosed Elderly ITP Patients in China-an Open Label Study Not yet recruiting NCT05311930 Phase 4 2.5mg/d Hetrombopag
28 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP): a Prospective, Randomized Controlled Trial Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
29 Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia Unknown status NCT02627417 Phase 3 Dapsone (Disulone®);Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";Prednisone (Cortancyl®)
30 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP)in Pregnancy: a Single-center Clinical Trial Unknown status NCT02270801 Phase 3 rhTPO
31 Thrombocytopenia in Gestational Period Unknown status NCT02751593 Phase 2, Phase 3 Dexamethasone
32 A Multicenter Prospective Randomized Study of Dexamethasone Combined With Decitabine Versus Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Unknown status NCT03252457 Phase 3 Decitabine;Dexamethasone
33 Efficacy of Helicobacter Pylori Eradication for the Treatment of Chronic or Persistent Immune Thrombocytopenic Purpura Patients With Moderate Thrombocytopenia: Multicenter Prospective Randomized Phase 3 Study Unknown status NCT03177629 Phase 3 treatment : H. pylori eradication
34 Proof of Concept; A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia Unknown status NCT03520049 Phase 3 Oseltamivir;Placebo
35 Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
36 A Multicenter Clinical Study of Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia Unknown status NCT03492515 Phase 3 recombinant human thrombopoietin;Platelet Concentrate
37 A Multicenter Randomized Study of Dexamethasone Combined With Rituximab, Cyclosporin and Intravenous Immunoglobulin in the Management of Newly Diagnosed ITP Patients Unknown status NCT02834468 Phase 3 DEX Combined With RTX, CSA and IVIG
38 A Multicenter Prospective Randomized Study of Rituximab Combined With Bortezomib Versus Rituximab in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Unknown status NCT03443570 Phase 3 Rituximab;Bortezomib
39 A Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune Thrombocytopenia Unknown status NCT01805648 Phase 3 rhTPO
40 Association of FC Gamma RIIIA Polymorphism and Thrombopoietin (THPO) Expression With Response to TPO Agonists in Refractory ITP and the Impact of Therapy on B and T Cells Subsets in the Patients With Mutated Genotypes Unknown status NCT02877212 Phase 3 Eltrombopag
41 A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia (ITP) Completed NCT04188379 Phase 3
42 A Single Arm, Open-label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP) Completed NCT02279173 Phase 3 Romiplostim
43 A Multicenter, Open-Label, Phase III Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP) Completed NCT05566990 Phase 3
44 Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Trial Completed NCT05621330 Phase 3 QL0911;Placebo comparator
45 A Randomized Study to Evaluate the Efficacy and Safety of Different Doses and Frequencies of Recombinant Human Thrombopoietin (rhTPO) in the Management of Primary Immune Thrombocytopenia (ITP) Completed NCT02139501 Phase 3 Recombinant Human Thrombopoietin (rhTPO)
46 Prospective, Non-Randomized, Open-label, Single-arm, Multi-Center Phase III Clinical Trial to Evaluate the Efficacy and Safety of IV-Globulin SN Inj.10% in the Patients Diagnosed With Immune Thrombocytopenia (ITP). Completed NCT02063789 Phase 3 Human immunoglobulin intravenous
47 A Multicenter Open-labeled Pilot Study on Recombinant Human Thrombopoietin in Management of Immune Thrombocytopenia in Pregnancy Completed NCT02391272 Phase 3 rhTPO
48 A Multicenter, Open-Label, Phase III Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP) Completed NCT03164915 Phase 3
49 A Multicentre Randomised Trial of First Line Treatment Pathways for Newly Diagnosed Immune Thrombocytopenia: Standard Steroid Treatment Versus Combined Steroid and Mycophenolate Completed NCT03156452 Phase 3 Mycophenolate Mofetil;Prednisolone
50 Rituximab as Second Line Treatment for ITP; A Multicenter, Randomized, Double Blind, Placebo-controlled, Phase III Study. "The RITP Study" Completed NCT00344149 Phase 3 Rituximab (Mabthera)

Search NIH Clinical Center for Thrombocytopenia Due to Platelet Alloimmunization

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Azathioprine
Cyclophosphamide
Immunoglobulins, Intravenous
Intramuscular immunoglobulin
Rho(D) Immune Globulin, human
Venoglobulin-I
Vinblastine
Vinblastine Sulfate

Genetic Tests for Thrombocytopenia Due to Platelet Alloimmunization

Genetic tests related to Thrombocytopenia Due to Platelet Alloimmunization:

# Genetic test Affiliating Genes
1 Autoimmune Thrombocytopenia 28

Anatomical Context for Thrombocytopenia Due to Platelet Alloimmunization

Organs/tissues related to Thrombocytopenia Due to Platelet Alloimmunization:

MalaCards : Bone Marrow, Bone, Skin, T Cells, Spleen, B Cells, Nk Cells

Publications for Thrombocytopenia Due to Platelet Alloimmunization

Articles related to Thrombocytopenia Due to Platelet Alloimmunization:

(show top 50) (show all 11831)
# Title Authors PMID Year
1
[Autoimmune thrombocytopenia, neutropenia and hemolysis]. 53 62
19225748 2009
2
Flow cytometric evaluation of platelet activation in chronic autoimmune thrombocytopenia. 53 62
16933254 2006
3
Gene frequencies of the human platelet antigen-3 in different populations. 53 62
15678278 2005
4
Combined thrombopoietin and platelet response to altitude in a patient with autoimmune thrombocytopenia. 53 62
15025089 2004
5
The diagnostic value of thrombopoietin level measurements in thrombocytopenia. 53 62
9657431 1998
6
Varicella-associated thrombocytopenia: autoantibodies against platelet surface glycoprotein V. 53 62
8888292 1996
7
[The effect of blood from patients with idiopathic thrombocytopenia and thrombopoietin on the thrombocyte count in the blood of mice]. 53 62
8657073 1995
8
Prevalence and significance of large granular lymphocytes in patients with immune thrombocytopenia. 62
36458562 2023
9
Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib. 62
36331249 2023
10
Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia. 62
36281771 2023
11
Pituitary apoplexy following adenoviral vector-based COVID-19 vaccination. 62
35464129 2023
12
Effects of COVID-19 vaccination on platelet counts and bleeding in children, adolescents, and young adults with immune thrombocytopenia. 62
36317671 2023
13
Development and internal validation of a clinical prediction model for the diagnosis of immune thrombocytopenia. 62
36121734 2022
14
Clinical efficacy of recombinant human thrombopoietin combined with glucocorticoids in the treatment of immune thrombocytopenia. 62
36094428 2022
15
Safety and efficacy of splenectomy for the treatment of chronic immune thrombocytopenia. 62
36175771 2022
16
Epistaxis duration predicts bleeding in immune thrombocytopenia: a cohort study. 62
36396166 2022
17
Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study. 62
36257098 2022
18
Cost-effectiveness of a quality improvement initiative for the clinical management of children with newly diagnosed immune thrombocytopenia. 62
36470460 2022
19
Excluding JAK2 V617F mutation analysis from the primary immune thrombocytopenia 'diagnosis of exclusion'. 62
36409925 2022
20
Comment on: Effects of COVID-19 vaccination on platelet counts and bleeding in children, adolescents, and young adults with immune thrombocytopenia. 62
36468649 2022
21
Progress on the efficacy and potential mechanisms of rapamycin in the treatment of immune thrombocytopenia. 62
36469708 2022
22
Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study. 62
36470677 2022
23
COVID-19: Vaccine-induced immune thrombotic thrombocytopenia. 62
36030503 2022
24
Expansion of Human Megakaryocyte-Lineage Progeny via Aryl Hydrocarbon Receptor Antagonism with CH223191. 62
35687264 2022
25
Clinical characteristics and prognostic factors in intracranial hemorrhage patients with hematological diseases. 62
36178488 2022
26
Vaccine-associated thrombocytopenia. 62
36265409 2022
27
Unusual phenotype of heterozygous LOF mutation in IKZF1, with common variable immunodeficiency presenting initially as immune thrombocytopenia: A case report. 62
35979904 2022
28
Splenectomy outcomes in patients with autoimmune cytopenias and persistent antiphospholipid antibodies. 62
36208143 2022
29
A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan. 62
36371366 2022
30
Suspected Immune Thrombocytopenic Purpura Induced by Lenalidomide for the Treatment of Myelodysplastic Syndrome with Deletion of Chromosome 5q: A Case Report. 62
36450481 2022
31
Blockage of CD72 reduces B cell proliferation in immune thrombocytopenic purpura, involving interleukin 1 and macrophage migration inhibitory factor secretion. 62
36326455 2022
32
Acute-type acquired hemophilia A after COVID-19 mRNA vaccine administration: A new disease entity? 62
36155279 2022
33
Idiopathic Thrombocytopenic Purpura associated with Inflammatory Bowel Disease: a multi-centre ECCO CONFER case series. 62
36455965 2022
34
Detection of Helicobacter pylori from Extracted Teeth of a Patient with Idiopathic Thrombocytopenic Purpura. 62
36422356 2022
35
Spectrum of Neurological Complications Following COVID-19 Vaccination in India. 62
36367066 2022
36
A case of hyperchylomicronemia associated with GPIHBP1 autoantibodies and fluctuating thyroid autoimmune disease. 62
36402671 2022
37
Molecular mimicry, hyperactive immune system, and SARS-COV-2 are three prerequisites of the autoimmune disease triangle following COVID-19 infection. 62
36182877 2022
38
Can SARS-CoV-2 trigger new onset of autoimmune disease in adults? A case-based review. 62
36338884 2022
39
Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure. 62
35791514 2022
40
Risk of thrombosis associated with antiphospholipid antibodies in immune thrombocytopenic Purpura: A single center retrospective study of 152 patients. 62
36435049 2022
41
Platelet satellitism in immune thrombocytopenic purpura. 62
36355464 2022
42
Danazol in Refractory Autoimmune Hemolytic Anemia or Immune Thrombocytopenia: A Case Series Report and Literature Review. 62
36355549 2022
43
Efficacy and steroid-sparing effect of tacrolimus in patients with autoimmune cytopenia. 62
36066607 2022
44
Clinical features and high-risk indicators of central nervous system involvement in primary Sjögren's syndrome. 62
36401063 2022
45
Heat shock protein-70 is elevated in childhood primary immune thrombocytopenia. 62
36369088 2022
46
Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia. 62
36374396 2022
47
Approach to the Patient with Adrenal Hemorrhage. 62
36404284 2022
48
Paraneoplastic syndromes: A focus on pathophysiology and supportive care. 62
35916756 2022
49
Potential mechanisms of vaccine-induced thrombosis. 62
35953336 2022
50
Relapses of Immune Thrombocytopenia after the second and booster doses of BNT162b2 Vaccine. 62
36327915 2022

Variations for Thrombocytopenia Due to Platelet Alloimmunization

ClinVar genetic disease variations for Thrombocytopenia Due to Platelet Alloimmunization:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SOCS1 NM_003745.2(SOCS1):c.476_480dup (p.Met161fs) MICROSAT Likely Pathogenic
977214 rs1470306246 GRCh37: 16:11348855-11348856
GRCh38: 16:11254998-11254999
2 SOCS1 NM_003745.2(SOCS1):c.24del (p.Ala9fs) DEL Likely Pathogenic
977213 rs2069587477 GRCh37: 16:11349312-11349312
GRCh38: 16:11255455-11255455

Expression for Thrombocytopenia Due to Platelet Alloimmunization

Search GEO for disease gene expression data for Thrombocytopenia Due to Platelet Alloimmunization.

Pathways for Thrombocytopenia Due to Platelet Alloimmunization

Pathways related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.22 THPO SYK PF4 ITGB3 ITGA2B CD4
2
Show member pathways
12.97 THPO SYK SELP PF4 MPL ITGB3
3 12.28 SYK SOCS1 MPL CD8A CD19
4
Show member pathways
12.18 SYK ICOSLG CD8A CD4
5 11.59 CD8A CD4 CCR6
6 11.52 CD8A CD4 CD19
7
Show member pathways
11.48 THPO SYK MPL ITGB3 ITGA2B GP5
8 11.47 CD19 ICOSLG IFNG-AS1 SYK
9 11.41 SOCS1 SELP ITGB3
10 11.39 THPO MPL ITGB3 ITGA2B GP5 GP1BA
11 11.32 ITGB3 ITGA2B GP5
12 11.24 ITGB3 ITGA2B FCGR2A
13 11.12 PF4 ITGB3 ITGA2B FCGR2A CD4

GO Terms for Thrombocytopenia Due to Platelet Alloimmunization

Cellular components related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016021 10.4 CCR6 CD19 CD4 CD8A FCGR2A FCGRT
2 membrane GO:0016020 10.4 CCR6 CD19 CD4 CD8A FCGR2A FCGRT
3 plasma membrane GO:0005887 10.09 CCR6 CD19 CD4 CD8A FCGR2A GP1BA
4 plasma membrane GO:0005886 10.09 CCR6 CD19 CD4 CD8A FCGR2A GP1BA
5 external side of plasma membrane GO:0009897 9.64 SELP MPL ITGB3 ITGA2B ICOSLG GP1BA
6 platelet alpha granule membrane GO:0031092 9.63 SELP ITGB3 ITGA2B
7 glycoprotein Ib-IX-V complex GO:1990779 9.62 GP5 GP1BA

Biological processes related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 10.06 PF4 FCGRT FCGR2C CD8A CD4 CCR6
2 platelet aggregation GO:0070527 9.91 MPL ITGB3 GP1BA
3 immune system process GO:0002376 9.87 SYK ICOSLG FCGR2A CD8A CD4 CD19
4 cell surface receptor signaling pathway GO:0007166 9.85 SYK GP1BA FCGR2C FCGR2A CD8A CD4
5 megakaryocyte development GO:0035855 9.73 GP1BA GP5 THPO
6 thrombopoietin-mediated signaling pathway GO:0038163 9.67 THPO MPL
7 platelet activation GO:0030168 9.56 SYK PF4 ITGB3 GP1BA
8 positive regulation of platelet activation GO:0010572 9.1 SELP GP5 GP1BA

Molecular functions related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 coreceptor activity GO:0015026 9.43 ITGB3 CD8A CD4
2 IgG binding GO:0019864 9.02 FCGRT FCGR2C FCGR2A

Sources for Thrombocytopenia Due to Platelet Alloimmunization

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....